Ulf Persson (Former)
1 – 10 of 51
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Dread and Risk Elimination Premium for the Value of a Statistical Life
(
- Contribution to journal › Article
- 2018
-
Mark
Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
(
- Contribution to journal › Article
-
Mark
Intraductal papillary mucinous neoplasms of the pancreas – a cost-effectiveness analysis of management strategies for the branch-duct subtype
(
- Contribution to journal › Article
- 2016
-
Mark
Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe
(
- Contribution to journal › Article
-
Mark
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
(
- Contribution to journal › Article
-
Mark
The End of the International Reference Pricing System?
2015) In Applied Health Economics and Health Policy(
- Contribution to journal › Article
-
Mark
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
(
- Contribution to journal › Article
- 2014
-
Mark
Willingness to pay for a new drug delivery in Parkinson patients.
(
- Contribution to journal › Article